ONE LEVEL DEEPER
FER
Warren Buffett frameworkThe Owner-OperatorBenjamin Graham frameworkThe Value ArchitectMichael Mauboussin frameworkThe Expectations EngineerHoward Marks frameworkThe Cycle WhispererPeter Lynch frameworkThe Everyday Edge

Management destroyed $1.3B buying at $115 what trades at $66, yet the market still pays 223x EBITDA.

cautiousBearishconviction

This framework sees a pendulum swung to euphoria — 223x EBITDA for toll roads that destroy capital, while insiders sell what they bought higher.

THE LENSES
PRICE VS VALUEdangerous

Is the price above or below what the business is worth?

EV/EBITDA of 223.03x in Q4'25, 98th percentile over 10 years
Earnings yield 0.52% vs treasury yield 4.33%, negative 3.81% spread
DCF fair value $90.75 implies 26.8% upside from current $66.47
Reverse DCF implies 4.09% perpetual growth, matching actual 4% growth
ROIC-WACC spread negative 5.15%, destroying value with every dollar invested

This framework sees extreme overvaluation — infrastructure assets trading at tech multiples while destroying capital. The DCF upside reflects generous assumptions about future cash flows that current returns don't support. When toll roads yield 88% less than treasuries, price has disconnected from value.

Expectations Gap: DCF vs Market
DCF FAIR VALUE
$91
27% discount
MARKET PRICE
$66
Price implies 4.1% growth · Trailing: 4.0%
THE PENDULUMeuphoric

Where is sentiment — at euphoria or despair?

Valuation multiples at historical extremes: EV/EBITDA 98th, P/B 95th, EV/Sales 95th percentile
Management spent 79.5% of operating cash flow on buybacks at $115.38 vs current $66.47
Institutional ownership declining from 30.99% to 30.47% as valuations peak
100% positive earnings surprises generate only 0.73% average price move

The pendulum has swung to euphoria — management buying aggressively at peak valuations while smart money exits. When perfect execution generates yawns, the crowd has already priced in miracles.

Price Targets
Chart: Price Targets
CYCLE TEMPERATURElate-cycle

Where are we in this company's cycle?

Operating margin recovered from -71.3% in Q2'23 to 7.8% in Q4'25
ROIC peaked at 7.59% in Q4'21, only quarter above cost of capital in 10 years
Working capital deteriorating with DSO rising from 59.94 to 72.01 days
Free cash flow positive at $925M TTM after volatile swings

This framework sees a business past its cyclical peak — margins recovered but remain below historical norms, ROIC chronically below cost of capital, and working capital efficiency deteriorating. The cycle suggests mean reversion ahead, not expansion.

Operating Margin
ASYMMETRYterrible

Does upside significantly exceed downside?

Trading at 48.1x P/E with 0.52% earnings yield vs 4.33% risk-free rate
DCF suggests 26.8% upside but requires maintaining current multiples
Buybacks destroyed $1.3B in value, -42.4% return from peak prices
Revenue growing 4% while valuation implies much higher growth

Applying this lens reveals terrible asymmetry — limited upside from already extreme valuations, while downside to historical multiples implies 70%+ losses. The margin of safety runs deeply negative.

P/E Ratio
KEY NUMBERS
VERDICT

This framework sees a classic pendulum extreme — wonderful toll road assets priced for perfection while destroying shareholder value through both operations and buybacks. When management pays $115 for shares worth $66 and the market still assigns 223x multiples, euphoria has overwhelmed judgment. The asymmetry is entirely negative. Would you pay 223x EBITDA for a toll booth?

This analysis applies Howard Marks's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Howard Marks. Educational purposes only. Not financial advice.

OTHER PERSPECTIVES
Michael Mauboussin framework
The Expectations Engineer
Leaning Bearish
Warren Buffett framework
The Owner-Operator
Bearish
Benjamin Graham framework
The Value Architect
Bearish
Peter Lynch framework
The Everyday Edge
Bearish
Explore
Cintas CorporationCTASRegeneron Pharmaceuticals, Inc.REGNBaker Hughes CompanyBKRZscaler, Inc.ZSAmgen Inc.AMGNThomson Reuters CorporationTRI
EDUCATIONAL ONLY · NOT FINANCIAL ADVICEv2